A review of targeted therapies for anemia in patients with lower-risk myelodysplastic syndromes and myelofibrosis that improve transfusion independence and hemoglobin levels.

Dr. Raajit Rampal studies myelofibrosis in the lab and in the clinic. An international phase 3 clinical trial of a new drug combination for treating the blood cancer myelofibrosis found that adding a ...

It's a very elegant endpoint in diseases that cause a lot of mortality within a year or two: glioblastomas, advanced pancreatic cancer, and acute leukemia in older adults. But in myelofibrosis ...

A machine learning model generated by a team from the European Society for Blood and Marrow Transplantation (EBMT) ...

Myelofibrosis is a type of blood cancer that's very similar to the end stages of polycythemia vera. It happens because too many abnormal cells break down in the bone marrow, replacing bone marrow ...

Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves ...

I'm Tania Jain, your host with our special guest today, Dr Krisstina Gowin, who is an associate clinical professor at City of Hope Comprehensive Cancer Center serving as the director of education ...

Doctors call this condition myelofibrosis. It’s rare, but abnormal bone marrow cells grow out of control. This can lead to acute myelogenous leukemia, a cancer of the blood and bone marrow.

Myelofibrosis is a rare blood cancer in which the bone marrow stem cells acquire a genetic defect, causing excessive production of blood cells along with a large number of inflammatory factors.

Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and over 30% will ...